logo

Spark Therapeutics (ONCE)



Trade ONCE now with
  Date
  Headline
12/2/2018 7:35:22 PM Spark Therapeutics Announces Updated Data On SPK-8011 From Ongoing Phase 1/2 Dose-escalation Trial In Hemophilia A
11/23/2018 1:22:10 AM Novartis Announces EU Approval For One-time Gene Therapy Luxturna
11/23/2018 1:16:17 AM Spark Therapeutics Says EC Granted Marketing Authorization For LUXTURNA
11/7/2018 7:52:43 AM Wedbush Is Lowering Spark Therapeutics (ONCE) FY18 Rev. Estimate To 66.7 M From 96.4 M
11/7/2018 7:52:23 AM Wedbush Is Raising Spark Therapeutics (ONCE) Q4 18 Rev. Estimate To 15.1 M From 12.1 M
11/7/2018 7:52:04 AM Wedbush Is Lowering Spark Therapeutics (ONCE) FY18 Estimate To -1.87 From -1.04
11/7/2018 7:51:48 AM Wedbush Is Cutting Spark Therapeutics (ONCE) Q4 18 Estimate To -1.51 From -1.40
11/7/2018 7:51:18 AM Wedbush Ups Spark Therapeutics (ONCE) To Neutral From Underperform With $40 Price Target
11/6/2018 7:38:19 AM Spark Therapeutics Q3 Net Loss Widens To $65 Mln From $47.3 Mln Last Year
9/21/2018 7:21:52 AM Spark Therapeutics Announces Positive CHMP Opinion For One-time Gene Therapy LUXTURNA In The European Union
8/7/2018 7:36:32 AM Spark Therapeutics Q2 Net Income $80.2 Mln Or $2.07/Shr Vs Loss $74.4 Mln Or $2.40/Shr Last Year
5/22/2018 2:02:30 AM Spark Therapeutics And Pfizer Announce Data From 15 Participants With Hemophilia B
5/9/2018 9:43:20 AM Wedbush Is Cutting Spark Therapeutics (ONCE) FY18 Rev. Estimate To 72.6 M From 239.5 M
5/9/2018 9:43:08 AM Wedbush Is Lowering Spark Therapeutics (ONCE) Q4 18 Rev. Estimate To 8.7 M From 16.4 M
5/9/2018 9:42:55 AM Wedbush Is Cutting Spark Therapeutics (ONCE) Q3 18 Rev. Estimate To 40.1 M From 48.1 M
5/9/2018 9:42:38 AM Wedbush Is Lowering Spark Therapeutics (ONCE) Q2 18 Rev. Estimate To 8.1 M From 150.4 M